EUVIMEDOpdag EUVIMED
Multizentrische Studie

Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real‐World Data From 17 Italian Centers

Francesca Caspani iD, Stefano Cavalieri iD, Ester Orlandi, Cristiana Bergamini iD, Carlo Resteghini, Elena Colombo, Arianna Ottini, Imperia Nuzzolese, Salvatore Alfieri iD, Aurora Mirabile, Alessandra Cassano, Paolo Bossi and 8 more

Head & Neck · 2025-07 · 47 (7) · 2040-2047

DOI: 10.1002/hed.28124 ↗

At a glance

Multizentrische Studie in Head & Neck, published online on 2025-03-03. Written by Francesca Caspani and 19 co-authors. Institution: Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. Major MEDLINE topics: Quinolines, Carcinoma, Adenoid Cystic, Phenylurea Compounds, Neoplasm Recurrence, Local. Cited 8 times so far (Crossref); 29 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Lenvatinib, a multi‐target tyrosine kinase inhibitor (MTKI), has demonstrated activity in recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC) in phase II studies.

Methods

This multicenter, retrospective study included patients with R/M ACC treated with lenvatinib. The primary endpoint was the overall response rate (ORR).

Results

Fifty‐one patients were included across 17 Italian sites. Forty‐six patients (90%) were evaluated for response: the ORR was 21.7%, with 10 patients achieving a partial response; 24 patients had a stable disease resulting in a disease control rate of 73.9%. At least one treatment‐related adverse event (TRAE) was recorded in all patients. The most frequent TRAEs of grade > 3 were hypertension (25.5%), stomatitis (17.6%), and fatigue (15.7%); one grade 5 TRAE (bleeding) was reported. Median OS was 16.1 months (95% CI 12.2‐NR) with six‐month PFS at 75.7%.

Conclusion

Lenvatinib confirmed its activity in the real‐world population. A higher than expected rate of grade > 3 stomatitis was reported.

Subjects

MeSH terms (MEDLINE)

QuinolinesCarcinoma, Adenoid CysticPhenylurea CompoundsNeoplasm Recurrence, LocalAntineoplastic AgentsSalivary Gland NeoplasmsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedItalyAdultTreatment OutcomeAged, 80 and overProtein Kinase Inhibitors

Author keywords

MTKIadenoid cystic carcinomalenvatinibsalivary gland cancersystemic therapy

Substances

lenvatinibQuinolinesPhenylurea CompoundsAntineoplastic AgentsProtein Kinase Inhibitors

Authors and institutions

  • Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Fondazione CNAO - Centro Nazionale di Adroterapia Oncologica, Radiotherapy, Pavia, Italy.
  • Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
  • CRO IRCCS, Head and Neck Medical Oncology, Aviano, Italy.
  • San Raffaele Hospital, Medical Oncology, Milan, Italy.

ORCID profiles: Francesca Caspani, Stefano Cavalieri, Cristiana Bergamini, Salvatore Alfieri, Laura D Locati

Cite

APA

Caspani, F., Cavalieri, S., Orlandi, E., Bergamini, C., Resteghini, C., Colombo, E., Ottini, A., Nuzzolese, I., Alfieri, S., Mirabile, A., Cassano, A., Bossi, P., Ibrahim, T., Cau, M. C., Ghiani, M., Bertolini, F., Ingargiola, R., Fontana, G., Licitra, L., & Locati, L. D. (2025). Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real‐World Data From 17 Italian Centers. Head & Neck, 47(7), 2040-2047. https://doi.org/10.1002/hed.28124

Vancouver

Caspani F, Cavalieri S, Orlandi E, Bergamini C, Resteghini C, Colombo E, et al. Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real‐World Data From 17 Italian Centers. Head & Neck. 2025;47(7):2040-2047. doi:10.1002/hed.28124

BibTeX
@article{Caspani2025,
  author = {Caspani, Francesca and Cavalieri, Stefano and Orlandi, Ester and Bergamini, Cristiana and Resteghini, Carlo and Colombo, Elena and Ottini, Arianna and Nuzzolese, Imperia and Alfieri, Salvatore and Mirabile, Aurora and Cassano, Alessandra and Bossi, Paolo and Ibrahim, Toni and Cau, Maria Chiara and Ghiani, Massimo and Bertolini, Federica and Ingargiola, Rossana and Fontana, Giulia and Licitra, Lisa and Locati, Laura D},
  title = {Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real‐World Data From 17 Italian Centers},
  journal = {Head & Neck},
  year = {2025},
  volume = {47},
  number = {7},
  pages = {2040--2047},
  doi = {10.1002/hed.28124}
}
Start for free →